Leafbuyer Technologies, Inc. Announces Record Results: 45% Increase in Quarterly Revenue and First Profitable Quarter as Public Company

February 15th, 2023 - Ryan Allway

Financial Highlights: Profitable: Net Income of $95,397 in Q2 from a Net Loss of $1,373,858 in the prior year Revenue rose 45% from $923,829 to $1,341,750 in the second quarter of fiscal year 2022 Gross Profit increased 174% from $261,770 to $716,146 in the same period Operating Expenses decreased 23% from $750,675 to $579,978   […]

Leafbuyer Announces Continued Strong Sales with a 33% increase in Quarterly Revenue

November 15th, 2022 - Ryan Allway

Financial Highlights: Revenue rose to $1,128,665 from $851,693 in the current quarter, compared to a year ago Gross Profit increased to $476,145 from $221,157 in the same period Operating Expenses decreased from $809,639 to $635,136 Revenue Increased 33% while Selling Expenses decreased 30%, based on expanding margins Gross Profit Increased 115% year to year   […]

Warren County, PA Police to Pilot Cannabix Marijuana Breathalyzer Technology

November 3rd, 2022 - Ryan Allway

  For immediate release. Vancouver, British Columbia, November 3, 2022: Cannabix Technologies Inc.(CSE: BLO, OTC PINK CURRENT: BLOZF) (the “Company”)  developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it has entered into a memorandum of understanding with the Warren County, Pennsylvania, District Attorney’s office to pilot the Company’s technology for detection of ∆9-tetrahydrocannabinol […]

Bioharvest Sciences Inc. Successfully Completes Cannabis R&D Program

March 23rd, 2022 - Ryan Allway

Now producing Cannabis biomass in large scale industrial bioreactors under the current R&D license. Commencing the process of transitioning the current Israeli Cannabis R&D license to a production license. Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – March 23, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) today announced that it has produced […]

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

February 23rd, 2022 - Ryan Allway

Completed a Drug Master File (“DMF”) process for CBD Active Pharmaceutical Ingredient (“API”) for the US Federal Drug Administration (“FDA”). Use of Canadian Drug Establishment Licence (“DEL”) to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025(i). […]

22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation

February 23rd, 2022 - Ryan Allway

New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial Lines BUFFALO, N.Y., Feb. 23, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today, together with its […]

Building the DoorDash or UberEats of Psychedelics

October 14th, 2021 - Ryan Allway

The psychedelics industry is rapidly growing, with more than 50 publicly traded companies worth billions of dollars. At the same time, the FDA’s approval of Spravato (esketamine) for treatment-resistant depression and the growing body of clinical evidence could provide further tailwinds for the industry over the coming decade and beyond. Unfortunately, many patients live in […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Psychedelics: Significant Investor Interest Despite the Pandemic

February 16th, 2021 - Ryan Allway

  The COVID-19 pandemic may be ravaging large swaths of the economy, but the stock market has consistently hit new record highs. After spending several years under-the-radar, the psychedelics industry is experiencing a renaissance driven by a combination of FDA-driven catalysts and soaring investor interest in a new class of potential blockbuster therapeutics.  Let’s take […]

Why Focus on Cannabis & Mushroom Extracts?

November 25th, 2020 - Ryan Allway

  Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion by 2024, which represents a respectable 8% compound annual growth rate. Let’s take a look […]

CB Therapeutics: Producing Rare Cannabinoid & Psychedelic Molecules at Scale

November 10th, 2020 - Ryan Allway

The cannabis industry has evolved from the legalization of dried cannabis to an increasingly detailed understanding of individual cannabinoids. While THC and CBD are the two most common, researchers are increasingly interested in CBC, THCV and other rare cannabinoids that could have specific and desirable effects on certain medical indications. The problem is that these […]

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

September 30th, 2020 - Ryan Allway

  DENVER, Colorado, USA – September 30th, 2020 – Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today: Download on Android Download on IOS […]

What Are Functional Mushrooms?

August 17th, 2020 - Ryan Allway

  Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, […]

THC BioMed Reports Growing Revenue & Profitability

April 22nd, 2020 - Ryan Allway

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations. THC BioMed Intl Ltd. (CSE: THC) recently recorded its […]

CFN Enterprises (OTCQB: CNFN) Names BlockChain Pioneer Tim Vasko to Board of Advisors

April 22nd, 2020 - Ryan Allway

“We are pleased to welcome Tim Vasko, the Founder and CEO of BlockCerts Blockchain, to the Board of Advisors of CFN Enterprises. Tim is a cloud and blockchain pioneer, creating companies that have processed billions of transactions, proprietary tracking applications and a patent providing secure virtual spaces,” said Brian Ross, Chairman and CEO of CFN Enterprises Inc.

Psychedelics: Investing in the Perfect BrainStorm

April 6th, 2020 - Ryan Allway

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space.  In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: […]

Cannabis Brands Want Their Own Store, CalEthos Deems it Essential

April 3rd, 2020 - Robin Lefferts

Cannabis Shelf Space Deemed Essential What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product […]

Israel Begins Cannabis Exports to Meet Unmet Medical Needs

March 30th, 2020 - Ryan Allway

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s […]

CannaTrac’s Diversified Revenue Streams Create a Baseline for Consistent, Sustainable Growth

March 25th, 2020 - Ryan Allway

The legal cannabis industry has had its ups and downs since its inception just a few years ago. Legislation and licensing decisions helped boost some companies, while overcapacity and regulatory issues depressed others. The best companies have found ways to diversify their revenue streams to generate consistent and sustainable growth over time.  In this article, […]

Isracann Enters JV for Near-Term Cannabis Farm Production Opportunity in Israel

March 24th, 2020 - Ryan Allway

24 MAR 2020 / CORPORATE NEWS Partnership advances time-to-market to under six months VANCOUVER, BC, — (March 24, 2020) – Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is […]

Adaptogens, Functional Beverages, and CBD

March 16th, 2020 - Ryan Allway

It’s a stressful world out there, and consumers know it. In growing numbers, people are looking for healthy foods, naturally sourced, to keep both themselves and the planet on a positive track. If those foods can also relieve stress and help people relax, all the better. Beverages are a prime example of the trend toward […]

Out with the Old: How CalEthos Is Giving Brands a Voice and Consumers an Educated Choice

March 3rd, 2020 - Robin Lefferts

For a revolutionary movement, the cannabis industry still seems to have a lot of “same old, same old.” Cannabis brands increasingly must face many of the challenges that other CPG businesses have long confronted – including distribution, retail visibility, and consumer education – while complying with regulations that leave one hand tied behind their backs. […]

Supreme Cannabis Focuses Organization and Reduces Cost Structure to Accelerate Profitable Growth

February 11th, 2020 - Ryan Allway

Corporate positions decreased by approximately 33% and operational positions decreased by approximately 13% Total number of positions decreased by approximately 15% across the Company New structure focuses the business on accelerating revenue growth in the Canadian market TORONTO, February 11, 2020 – The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: […]

THC BioMed Intl Ltd. Turns a Profit as Revenue Breaks $1 Million

January 28th, 2020 - Robin Lefferts

Canada’s cannabis sector has experienced a sharp sell-off over the past year, with the Marijuana Index’s Canadian Index moving from a high of $727 in March to a low of $196 in November. Rather than looking solely at growth in production capacity, many investors are shifting their focus to tangible revenue growth and profitability. Profitable […]

Supreme Cannabis 2020, A Simple Approach On The Path To Profitability

January 23rd, 2020 - Ryan Allway

Many expect 2020 to go down as the shakeout year for the Canadian cannabis industry; the year where winners will make their way to the top and companies with weak fundamentals will be ruled out. Of the potential winners, The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) is one Canadian player that stands out with its […]

CannaTrac Aims to Become the Go-To Payment Solution for Cannabis

January 23rd, 2020 - Ryan Allway

The legal cannabis industry is projected to grow from $12.4 billion in 2019 to $23 billion by 2025, according to New Frontier Data, driven by the liberalization of medical and adult-use laws around the country. While federal regulations have started to catch up, the industry continues to struggle with a lack of access to the […]

Studies Show Millions of Americans Driving Under the Influence of Marijuana

January 13th, 2020 - Robin Lefferts

As many states have legalized marijuana in some form, the safety concerns surrounding cannabis-impaired driving are growing. According to the US Centers for Disease Control and Prevention, recent national estimates of drivers who operate a car under the influence of marijuana are in the millions. CNN discussed these findings in an article, highlighting the fact […]

Supreme Cannabis Announces Leadership Transition as Company Accelerates Transformation into Premium Cannabis CPG Company

January 6th, 2020 - Ryan Allway

Supreme Cannabis Board Director and former President of Starbucks Coffee Canada, Colin Moore, appointed Interim President and CEO. Navdeep Dhaliwal departs Company, effective immediately. Interim CEO to leverage successful track record to accelerate growth and transformation strategy, while improving speed to market and rightsizing operating and capital spends. Search for new CEO to begin immediately. […]

CannaTrac CEO on Federal Agencies’ Relaxed Financial Services Rules for Hemp-Related Companies

December 23rd, 2019 - Ryan Allway

To say finding financial services has been difficult for cannabis and hemp companies in recent years is a gross understatement. For many, even understanding regulations has been arduous at best. A lack of continuity in regulations between states and federal laws has traditional banks steering clear of the industry for fear of backlash, but that […]

Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at,, or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit:

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer